Artificial Intelligence in Cancer Diagnostics Market Size & Share 2025 – 2034

Artificial Intelligence in Cancer Diagnostics Market Size

The global artificial intelligence in cancer diagnostics market was estimated at USD 331 million in 2024. The market is expected to grow from USD 406.7 million in 2025 to USD 2.8 billion in 2034, at a CAGR of 23.7%.

Recent developments in digital pathology, imaging technology, and machine learning enhancing early detection and diagnostic precision have accelerated market growth. Globally, cancer remains a major public health concern, with the World Health Organization (WHO) reporting 20 million new cases and over 10 million deaths in 2022. Among these, breast, lung, colorectal, and prostate cancers are the most commonly diagnosed, highlighting a significant demand for diagnostic systems that leverage AI for greater accuracy and efficiency.
 

AI software streamlines the diagnostic workflow by integrating large volumes of clinical data with radiological images and histopathological slides. The application of convolutional neural networks (CNNs) and natural language processing (NLP) enhances abnormality detection, thereby improving cancer diagnosis across various cancer types. In addition, the application of AI to liquid biopsy, genomics, and next-generation sequencing is accelerating the development of non-invasive cancer screening methods. These advancements enable early-stage preventive measures, significantly improving survival rates particularly for pancreatic and ovarian cancers, which are often diagnosed at advanced stages.
 

Artificial intelligence in cancer diagnostics encompasses all AI-based systems and solutions designed to enhance accuracy, efficiency, and early detection. These include advanced imaging technologies, predictive analytics tools, and personalized treatment approaches all of which contribute to improved clinical outcomes and are transforming cancer care.
 

Artificial Intelligence in Cancer Diagnostics Market Trends

• The market for artificial intelligence in cancer diagnostics is experiencing rapid growth, driven by the increasing adoption of AI-based imaging, predictive analytics, and precision oncology technologies that enhance diagnostic accuracy and reduce detection time.
   
• The International Agency for Research on Cancer (IARC) projects that global cancer cases will exceed 30.2 million by 2040, up from an estimated 20 million in 2024, with annual deaths expected to surpass 16 million. This surge underscores the urgent need for AI-based diagnostic systems that are both automated and scalable.
   
• Advancements in oncology information systems and AI-powered imaging are enhancing the detection capabilities of certain cancer types and enabling earlier interventions ultimately improving treatment outcomes, patient survival rates, and overall health.
   
• Studies show that implementing AI in mammogram screening improves breast cancer detection rates by 9.6% compared to conventional methods. Breast cancer remains the most commonly diagnosed cancer globally, with 2.3 million new cases in 2023, while lung cancer is the deadliest, accounting for approximately 1.8 million deaths annually representing 18% of all cancer-related fatalities.
   
• AI technologies are also playing a critical role in cancer screening programs. For instance, in lung cancer detection, AI algorithms have demonstrated over 94% accuracy in identifying malignant nodules on chest CT scans outperforming radiologists in some studies. These tools have the most significant impact on early-stage breast, lung, and colorectal cancers, which collectively account for over 6 million new cases each year.
   
• The use of AI on 500 million patient records allows for the identification of patterns related to cancer recurrence, metastasis, and drug resistance. Additionally, these models are projected to improve long-term outcomes and reduce rehospitalization costs by up to 25%. These advancements are revolutionizing cancer detection, early-stage treatment, and global healthcare accessibility.
   

Trump Administration Tariffs

• Changes in global regulations will impact the innovation and use of AI technologies in cancer diagnostics. Countries will become stricter with data laws and patient privacy and will place limitations on data transfer across borders. These developments will create new and complex challenges for AI companies using international datasets for their algorithms.
   
• In response to these changes, businesses will invest in local compliance strategies, establish data centers, and develop secure AI frameworks, along with country specific diagnostic models. Companies will use these approaches to meet jurisdictional objectives without compromising the quality of results through federated learning and privacy-preserving AI frameworks.
   
• Short-term impacts will include higher operational costs, more complicated international scaling of AI solutions, and delayed timelines for new product launches. Enhanced internal compliance capabilities will be developed alongside the expansion of competitive partnerships with local private healthcare systems, research bodies, and regulatory organizations.
   

Artificial Intelligence in Cancer Diagnostics Market Analysis

In 2021, the global market was valued at USD 179.1 million. The following year, it saw a slight increase to USD 219.5 million, and by 2023, the market further climbed to USD 269.5 million.
 

Based on the component, the market is segmented into software solutions, hardware, and services. The software solutions segment dominated the market with USD 162.4 million in 2024.
 

• Image analysis, data analytics, and predictive modeling are some of the processes offered under the software solutions segment of market.
   
• These solutions improve the effectiveness of computer-aided diagnoses with the use of machine learning, enabling clinicians to identify cancers early and tailor care plans, improving outcomes. Important components comprise of radiology imaging, pathology with genomic data integration, automated workflows, and mitigation of errors in diagnostics.
   
• The growing use of cloud-based ecosystems and AI-based clinical workflows increases need, accessibility, and scalability, further driving demand. With ongoing developments in deep learning as well as processing of multimodal data, the software solutions segment is poised for significant growth, due to global demands for precision oncology and enhanced cancer care services and outcomes.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on cancer type, the AI in cancer diagnostics market is divided into breast cancer, lung cancer, colorectal cancer, prostate cancer, and other cancer types. The breast cancer segment accounted for a significant market share of 29.4% in 2024.
 

• The breast cancer segment dominates the market, due to its high prevalence as well as the need to accurately detect it at an early stage.
   
• As reported by the Centers for Disease Control and Prevention (CDC), around 272,454 new cases of breast cancer were recorded in females in the U.S. in the year 2021, while 42,211 females died due to breast cancer in 2022, highlighting the critical demand for cutting-edge breast cancer diagnostics advancement in this segment.
   
• AI tools such as advanced imaging systems, predictive algorithms, and other predictive tools significantly improve patient outcomes by increasing the accuracy of mammograms, biopsies, and risk assessments.
   
• These technologies improve clinician’s ability to tailor treatments mitigating false positive results, and personally designed treatment options. In addition, the accelerated integration of AI solutions to healthcare infrastructures globally strengthens market opportunities.
   

Based on end use, the artificial intelligence in cancer diagnostics market is divided into hospitals, diagnostic laboratories, and other end users. The hospital segment dominated the market in 2024 and is expected to reach USD 1.5 billion by 2034.       
 

• Hospitals play a crucial role in the artificial intelligence-driven cancer diagnostics market. These institutions readily adopt advanced imaging, digital pathology, and predictive analytics, which enhance diagnostic accuracy and improve workflow efficiency through automation.
   
• Additionally, hospitals leverage AI for integrating data relevant to proactive and personalized treatment plans, as well as monitoring treatment outcomes. In response to the growing global cancer burden, hospitals are increasing investments in AI technologies to meet the rising demand for diagnostics, improve patient outcomes, and reduce operational strain.
   

The North America artificial intelligence in cancer diagnostics market held the largest market share of 41.3% in 2024 in the global market, and it is anticipated to expand at 23.5% CAGR over the forecast period. The U.S. market was valued at USD 125.5 million in 2024.
 

• The U.S. leads the global market, driven by high level of research and development, well-established healthcare ecosystem, and increasing cases of cancer.  
   
• Estimates from the American Cancer Society indicate nearly 2 million new cancer cases and approximately 609,820 cancer-related deaths in 2024. Breast, lung, prostate, and colorectal cancers continue to be the most commonly diagnosed, heightening the need for efficient diagnostic tools.
• AI technologies improve the chances of detecting cancer earlier and enable the customization of treatment regimens through imaging evaluations, biomarker identification, and predictive analytics.
   
• Additionally, FDA support and collaborations between academic institutions and startup companies further enhance innovation. With the aid of advanced technologies such as deep learning and sophisticated imaging techniques, the U.S. market is expected to grow significantly.
   

Europe artificial intelligence in cancer diagnostics market accounted for USD 109.3 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Increased investments by the German, French, and British governments into AI-based diagnostic imaging, digital pathology, and genomics have been the primary driving factors behind the market growth.
   
• Concerns over rising cancer rates, combined with developed healthcare systems and favorable policies, are expected to further drive market expansion.
   
• The European Commission’s Horizon Europe program has allocated over EUR 1 billion for AI in health innovation, including oncology diagnostics.
   
• In addition to economic incentives, private-public partnerships between technology companies and research institutes are driving advancements in precision oncology.
   

The Germany artificial intelligence in cancer diagnostics market is experiencing robust growth in Europe market.
 

• Germany leads the European market in AI-powered cancer diagnostics due to government funding and programs such as AI Made in Germany. The country focuses on applying AI into the existing healthcare system in Germany, especially in the fields of radiology and pathology.
   
• In addition, the collaboration of the universities with the tech companies and hospitals has resulted in groundbreaking innovations for cancer detection.
   
• Germany emphasizes data protection and the ethical use of AI, while leveraging its expertise in machine learning and precision diagnostics to improve cancer patient survival rates and optimize healthcare system processes.
   

The Asia Pacific artificial intelligence in cancer diagnostics market witnessed substantial growth of 24% during the analysis period.
 

• The rapid growth of the Asia Pacific market for AI in cancer diagnostics is fueled by the rising cancer incidence, growing healthcare expenditures, and increasing digitalization within the region.
   
• AI technologies are being implemented for enhanced imaging diagnostics, pathology, and genomic analysis by countries such as China, India, Japan, and South Korea to facilitate early detection and treatment.
   
• China leads in AI healthcare patents and funding, while Japan’s aging population is accelerating demand for AI-assisted oncology tools.
   
• Moreover, other factors, such as India's National Digital Health Mission and public-private partnerships in Southeast Asia, are also supporting the implementation of AI technology, that drives the growth of the market.
   

The Brazil artificial intelligence in cancer diagnostics market is experiencing robust growth in Latin America market.
 

• Brazil is actively integrating AI into the public health system for cancer detection programs to provide access to proper care for citizens lacking basic healthcare services.
   
• Challenges such as limited infrastructure and funding persist, but government initiatives and partnerships are paving the way for AI-driven advancements in oncology care across the country.
   

The Saudi Arabia artificial intelligence in cancer diagnostics market is witnessing substantial growth in Middle East and Africa.
 

• The market in Saudi Arabia is experiencing significant growth, driven by government initiatives under Vision 2030 to modernize healthcare infrastructure. Government funding and investment saw an increased number of AI technology tailored to the rising cancer patients in Saudi Arabia.
   
• Moreover, the partnerships of healthcare services and technology firms are improving operational accuracy and efficiency. AI technologies are widely used in radiology, pathology, and genomics where they facilitate the early detection of cancer and the tailored treatment design.
   

Artificial Intelligence in Cancer Diagnostics Market Share

The top 5 companies in the market, such as Microsoft, GE Healthcare, Paige AI, Tempus, and Siemens Healthineers, account for ~65% of the market share. These companies maintain their dominance through advancements in AI-powered imaging, digital pathology, and predictive analytics, addressing the increasing demand for early cancer detection and precision diagnostics. Firms are expanding their capabilities with deep learning algorithms, multi-omics data integration, and cloud-based diagnostic platforms to enhance clinical decision-making. Companies such as Path AI, SkinVision, Vuno, and Nanox Imaging are also making significant strides in niche areas of cancer diagnostics, contributing to market diversity and driving forward innovation in detection, workflow automation, and personalized care.
 

AI in Cancer Diagnostics Market Companies

Major players operating in artificial intelligence in cancer diagnostics industry are:

• Cancer Center.ai
• EarlySign
• Flatiron
• GE Healthcare
• Kheiron Medical Technologies
• Microsoft
• Nanox Imaging
• Paige AI
• Path AI
• Siemens Healthineers
• SkinVision
• Tempus
• Therapixel
• Vuno
   
• GE Healthcare focuses on AI-powered imaging technologies used in cancer diagnostics, particularly in CT, MRI, and PET-CT systems. Its Edison AI platform supports clinical decision-making by integrating imaging data with patient records. For example, GE’s AI algorithms assist in detecting lung nodules and breast lesions, aiming to improve early cancer identification and radiology workflows.
   
• Siemens Healthineers integrates AI into diagnostic imaging and clinical decision support systems. Its AI-Rad Companion is used to assist in the detection of lung cancer and liver lesions from CT scans. The company also supports oncology diagnostics through syngo.via, a platform used in multi-modality image analysis and therapy planning.
   
• Paige AI applies deep learning to digital pathology, analyzing whole-slide images from tissue biopsies. Paige Prostate, for instance, is an FDA-approved AI model used to assist in identifying prostate cancer, supporting pathologists in interpreting biopsy slides with large-scale histological data.
   

Artificial Intelligence in Cancer Diagnostics Industry News

• In February 2025, Cancer Center.ai partnered with Microsoft Azure to leverage artificial intelligence for accelerating cancer diagnostics, improving imaging workflows, and enhancing diagnostic accuracy in clinical oncology across healthcare institutions.
   
• In November 2024, GE HealthCare and RadNet collaborated to revolutionize imaging systems by integrating smart technology and accelerating AI adoption. This partnership aims to advance precision diagnostics and improve outcomes in cancer care, showcasing innovation in artificial intelligence in cancer diagnostics.
   
• In January 2023, Paige partnered with Microsoft to revolutionize cancer diagnosis and treatment using advanced pathology AI, aiming to enhance diagnostic precision and improve patient outcomes, marking a significant milestone in artificial intelligence in cancer diagnostics.
   

The artificial intelligence in cancer diagnostics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Component

• Software solutions
• Hardware
• Services

Market, By Cancer Type

• Breast cancer
• Lung cancer
• Colorectal cancer
• Prostate cancer
• Other cancer types

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE